Researchers analyzing hundreds of brain scans report that the entorhinal cortex and amygdala begin losing tissue earlier in Alzheimer's than the hippocampus, the region that has long been the main focus when doctors look for the disease. The findings were published in NeuroImage Reports and are being presented at Neuroscience 2026, the annual meeting of the Society for Neuroscience.
The team drew on MRI and PET scans from two independent research projects, the Alzheimer's Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study. The scans followed people at different stages, including those with no symptoms, those with cognitive impairment, and patients who ultimately died from the disease. In both groups, the entorhinal cortex and amygdala showed greater relative tissue loss during the early stages than the hippocampus did.
Senior author Michael Miller, a biomedical engineer, said the changes can appear as much as a decade before clinical symptoms, which he described as a 5-to-10-year window in which the brain is already changing. Co-author Marilyn Albert, director of the Johns Hopkins Alzheimer's Disease Research Center, said the goal is to treat people before symptoms develop so the disease might be delayed or even stopped.
The study also linked the tissue loss to tau, a protein that normally helps stabilize nerve cells but can build up into tangles in Alzheimer's. Using PET imaging and digital pathology, the researchers found that areas of gray matter shrinkage overlapped with regions showing tau-related changes. The authors suggest that measuring both regions could eventually improve predictions of who will develop cognitive decline, and they note that as imaging becomes cheaper and more available, the approach could become practical.
The researchers are clear that this is not yet a diagnostic tool. The study identifies potential early biomarkers but does not establish a clinical test that can predict Alzheimer's years in advance. The next step is to examine the molecular changes around abnormal tau accumulation in these regions, which Miller said could eventually point toward therapies.